Market Research

Anticancer Drugs Market (Drug Type: Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs; and Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 226 Pages Transparency Market Research Pvt. Ltd. December, 2023 TNPR18480093
Best Price Guarantee
Price from $5,795
Length 226 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date December, 2023
SKU TNPR18480093

Anticancer Drugs Market (Drug Type: Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs; and Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031


Anticancer Drugs Market – Scope of Report

TMR’s report on the global anticancer drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anticancer drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticancer drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anticancer drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anticancer drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anticancer drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anticancer drugs market.

The report delves into the competitive landscape of the global anticancer drugs market. Key players operating in the global anticancer drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anticancer drugs market profiled in this report.

Key Questions Answered in Global anticancer drugs Market Report
  • What is the sales/revenue generated by anticancer drugs across all regions during the forecast period?
  • What are the opportunities in the global anticancer drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Anticancer Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global anticancer drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anticancer drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anticancer drugs market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anticancer Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2023–2031
6.3.1. Cytotoxic Drugs
6.3.1.1. Alkylating Agents
6.3.1.2. Antimetabolites
6.3.1.3. Others
6.3.2. Targeted Drugs
6.3.2.1. Monoclonal Antibodies
6.3.2.2. Tyrosine Kinase Inhibitors
6.3.2.3. Others
6.3.3. Hormonal Drugs
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Therapy Type, 2023–2031
7.3.1. Chemotherapy
7.3.2. Targeted Therapy
7.3.3. Immunotherapy
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Type
8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2023–2031
8.3.1. Lung Cancer
8.3.2. Breast Cancer
8.3.3. Leukemia
8.3.4. Colorectal Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Therapy Type
9. Global Anticancer Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2023–2031
10.3.1. Cytotoxic Drugs
10.3.1.1. Alkylating Agents
10.3.1.2. Antimetabolites
10.3.1.3. Others
10.3.2. Targeted Drugs
10.3.2.1. Monoclonal Antibodies
10.3.2.2. Tyrosine Kinase Inhibitors
10.3.2.3. Others
10.3.3. Hormonal Drugs
10.4. Market Value Forecast, by Therapy Type, 2023–2031
10.4.1. Chemotherapy
10.4.2. Targeted Therapy
10.4.3. Immunotherapy
10.4.4. Others
10.5. Market Value Forecast, by Cancer Type, 2023–2031
10.5.1. Lung Cancer
10.5.2. Breast Cancer
10.5.3. Leukemia
10.5.4. Colorectal Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Therapy Type
10.7.3. By Cancer Type
10.7.4. By Country
11. Europe Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2023–2031
11.3.1. Cytotoxic Drugs
11.3.1.1. Alkylating Agents
11.3.1.2. Antimetabolites
11.3.1.3. Others
11.3.2. Targeted Drugs
11.3.2.1. Monoclonal Antibodies
11.3.2.2. Tyrosine Kinase Inhibitors
11.3.2.3. Others
11.3.3. Hormonal Drugs
11.4. Market Value Forecast, by Therapy Type, 2023–2031
11.4.1. Chemotherapy
11.4.2. Targeted Therapy
11.4.3. Immunotherapy
11.4.4. Others
11.5. Market Value Forecast, by Cancer Type, 2023–2031
11.5.1. Lung Cancer
11.5.2. Breast Cancer
11.5.3. Leukemia
11.5.4. Colorectal Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Therapy Type
11.7.3. By Cancer Type
11.7.4. By Country/Sub-region
12. Asia Pacific Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2023–2031
12.3.1. Cytotoxic Drugs
12.3.1.1. Alkylating Agents
12.3.1.2. Antimetabolites
12.3.1.3. Others
12.3.2. Targeted Drugs
12.3.2.1. Monoclonal Antibodies
12.3.2.2. Tyrosine Kinase Inhibitors
12.3.2.3. Others
12.3.3. Hormonal Drugs
12.4. Market Value Forecast, by Therapy Type, 2023–2031
12.4.1. Chemotherapy
12.4.2. Targeted Therapy
12.4.3. Immunotherapy
12.4.4. Others
12.5. Market Value Forecast, by Cancer Type, 2023–2031
12.5.1. Lung Cancer
12.5.2. Breast Cancer
12.5.3. Leukemia
12.5.4. Colorectal Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Therapy Type
12.7.3. By Cancer Type
12.7.4. By Country/Sub-region
13. Latin America Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2023–2031
13.3.1. Cytotoxic Drugs
13.3.1.1. Alkylating Agents
13.3.1.2. Antimetabolites
13.3.1.3. Others
13.3.2. Targeted Drugs
13.3.2.1. Monoclonal Antibodies
13.3.2.2. Tyrosine Kinase Inhibitors
13.3.2.3. Others
13.3.3. Hormonal Drugs
13.4. Market Value Forecast, by Therapy Type, 2023–2031
13.4.1. Chemotherapy
13.4.2. Targeted Therapy
13.4.3. Immunotherapy
13.4.4. Others
13.5. Market Value Forecast, by Cancer Type, 2023–2031
13.5.1. Lung Cancer
13.5.2. Breast Cancer
13.5.3. Leukemia
13.5.4. Colorectal Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Therapy Type
13.7.3. By Cancer Type
13.7.4. By Country/Sub-region
14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2023–2031
14.3.1. Cytotoxic Drugs
14.3.1.1. Alkylating Agents
14.3.1.2. Antimetabolites
14.3.1.3. Others
14.3.2. Targeted Drugs
14.3.2.1. Monoclonal Antibodies
14.3.2.2. Tyrosine Kinase Inhibitors
14.3.2.3. Others
14.3.3. Hormonal Drugs
14.4. Market Value Forecast, by Therapy Type, 2023–2031
14.4.1. Chemotherapy
14.4.2. Targeted Therapy
14.4.3. Immunotherapy
14.4.4. Others
14.5. Market Value Forecast, by Cancer Type, 2023–2031
14.5.1. Lung Cancer
14.5.2. Breast Cancer
14.5.3. Leukemia
14.5.4. Colorectal Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Therapy Type
14.7.3. By Cancer Type
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bayer AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AstraZeneca
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Merck & Co., Inc
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. CELGENE CORPORATION
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Amgen Inc
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings